Humulin M3 Kwikpen (Mixture 3) (Insulin Human (Rdna))

Humulin M3 Kwikpen (Mixture 3) is used as part of a comprehensive diabetes management plan to improve glycemic control in adults with insulin‑dependent conditions.

• Adjunct therapy for type 1 diabetes mellitus when basal and bolus insulin are required.
• Adjunct therapy for type 2 diabetes mellitus inadequately controlled with oral agents alone.
• Used in combination with dietary counseling and regular blood‑glucose monitoring.
• May be prescribed when a rapid‑acting insulin component is needed for mealtime coverage.
• Suitable for patients who prefer a pre‑filled pen device for ease of administration.

• Insulin human in Humulin M3 Kwikpen binds to insulin receptors on the surface of muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation of the β‑subunit, initiating the intracellular PI3‑K/Akt signaling cascade. This cascade promotes translocation of GLUT‑4 transporters to the cell membrane, enhancing glucose uptake, and suppresses hepatic gluconeogenesis, thereby lowering circulating blood‑glucose concentrations. The overall effect is a rapid reduction in post‑prandial glucose spikes and a sustained basal glucose‑lowering effect.

Adverse reactions reported with Humulin M3 Kwikpen can be grouped into common, typically mild events, and serious, less frequent events that may require medical attention.

Common

• Hypoglycemia (low blood glucose) presenting as sweating, tremor, or dizziness.
• Injection‑site reactions such as redness, swelling, or itching.
• Lipodystrophy, including lipoatrophy or lipohypertrophy at the injection site.
• Weight gain associated with improved glycemic control.
• Unexplained fatigue or malaise shortly after injection.

Serious

• Severe hypoglycemia with loss of consciousness or seizures.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Edema or fluid retention, particularly in patients with cardiac disease.
• Persistent hyperglycemia indicating possible insulin resistance or dosing error.
• Acute pancreatitis presenting with abdominal pain and elevated enzymes.

When prescribing Humulin M3 Kwikpen, clinicians should consider several precautions to minimize risks and ensure appropriate use.

• Assess renal and hepatic function before initiating therapy, as impairment may alter insulin clearance.
• Adjust dose in patients with variable eating patterns or increased physical activity to avoid hypoglycemia.
• Monitor for signs of hypoglycemia during pregnancy; insulin requirements may change.
• Educate patients on proper injection technique and rotation of sites to prevent lipodystrophy.
• Review concomitant use of other antidiabetic agents to avoid additive glucose‑lowering effects.
• Advise caution in patients with cardiovascular disease, as fluid retention can exacerbate heart failure.

Humulin M3 Kwikpen may interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment, which can cause severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms, increasing risk of unnoticed low glucose.
• High‑dose corticosteroids that markedly raise blood glucose, potentially overwhelming insulin effect.

Use with caution

• Oral antidiabetic agents such as sulfonylureas or meglitinides, which may potentiate hypoglycemia.
• MAO‑inhibitors and certain antidepressants that can affect glucose metabolism.
• Diuretics that may alter electrolyte balance and affect insulin absorption.